Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response (MADDRE)
A Cross-sectional Observational Study to Describe Treatment Management of Patients With Major Depressive Disorder (MDD) and Inadequate Response to Antidepressants in Greece
Sponsor: AstraZeneca
Listed as NCT01397903, this observational or N/A phase trial focuses on Major Depressive Disorder and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Sep 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ag. Nikolaos, Greece , Agrinio, Greece , Aigáleo, Greece , Arta, Greece , Athens, Greece , Chaïdári, Greece , Dafni, Greece , Glyfada, Greece , Heraklio, Greece , Ioannina, Greece and 17 more locations